{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:37Z","timestamp":1786119337152,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,13]]},"DOI":"10.1097\/qad.0b013e328331a456","type":"journal-article","created":{"date-parts":[[2009,10,28]],"date-time":"2009-10-28T03:22:47Z","timestamp":1256700167000},"page":"2364-2366","source":"Crossref","is-referenced-by-count":22,"title":["Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus"],"prefix":"10.1097","volume":"23","author":[{"given":"Isabelle","family":"Thuret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Tamalet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Reliquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine","family":"Firtion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Tricoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Frange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Auma\u00eetre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled study","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R2-16-20210130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-16-20210130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-16-20210130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment experienced HIV-1-infected patients in DUET-1: 24 week results from a randomized, double blind, placebo controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"R5-16-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment experienced HIV-1-infected patients in DUET-2: 24 week results from a randomized, double blind, placebo controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"R6-16-20210130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER1","volume":"21","author":"Katlama","year":"2007","journal-title":"AIDS"},{"key":"R7-16-20210130","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e3280b07b47","article-title":"Week 24 efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: POWER2","volume":"21","author":"Haubrich","year":"2007","journal-title":"AIDS"},{"key":"R8-16-20210130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e328331a456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:05:16Z","timestamp":1786039516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200911130-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,13]]},"references-count":8,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328331a456","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11,13]]}}}